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Conclusions: To our knowledge, this is the first paper 
addressing patient-reported acute GI and GU toxicity data 
from large prospective studies. We identified clinically 
relevant reductions in acute GI and GU toxicity for patients 
treated with IG-IMRT compared to 3D-CRT. This is the result 
of significantly lower doses to OARs, achieved by improved 
techniques and tighter margins. Since delivered dose to OARs 
as well as acute toxicity itself are known predictors of late 
toxicity, we expect this will eventually translate in lower late 
toxicity levels.  
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Purpose/Objective: According to European and American 
guidelines, treatment options after radical prostatectomy are 
adjuvant radiotherapy or early salvage radiotherapy (RT). In 
both cases, only prostate bed irradiation is recommended 
because any remaining tumor or local recurrence are most 
frequently located at this site. Recurrence in other sites can 
therefore be overlooked. In this study, we aimed to evaluate 
the incidence and location of visible recurrence on pelvic 
multiparametric MR (mpMR), to define the radiological 
criteria of local recurrence and lymph node spread after 
radical prostatectomy, and to determine the association of 
clinical and pathologic variables with imaging results. 
Materials and Methods: We retrospectively reviewed the 
clinical records and mpMR studies of 70 patients with PSA 
recurrence after radical prostatectomy. To investigate any 
association between clinical and pathological variables with 
imaging results, we recorded initial PSA, pT stage, 
pathological Gleason score, presence and location of 
extracapsular extension, vesicle involvement, margin status, 
number of positive margins, postoperative PSA, PSA at the 
time of MRI, PSA doubling time and open versus laparoscopy 
or robotic prostatectomy. Statistical analysis was performed 
using T-test and univariate and multivariate studies. 
MR protocol included T2 weighted TSE sequences, diffusion-
weighted sequences, calculation of apparent diffusion 
coefficient values, and dynamic contrast-enhanced MR with 
time curves generated from regions of interest. 
Results: mpMR was positive in 33/70 patients. We found no 
statistically significant differences between patients with 
positive or negative mpMR studies for any variables. Local 
recurrence occurred in 27 patients: perianastomotic (19), 
periurethral (1), right posterior to the bladder (3), left 
posterior to the bladder (1), right seminal vesicle bed (1), 
left seminal vesicle bed (1), and penile bulb (1). mpMR 
detected positive lymph nodes in 7 patients (14 
regions)(10%): right external iliac (5), left external iliac (4), 
right common iliac (2), left internal iliac (1), right obturator 
(1) ,and left obturator (1). 
Lower PSA doubling time was associated with positive lymph 
nodes (5.83 vs 17.35 months (p=0.05). Lymph node and local 
recurrence showed the same functional parameters in mpMR. 
Conclusions: Nearly half the patients with PSA-recurrence 
after radical prostatectomy had visible disease in mpMR. 
Incidence of positive lymph nodes should be considered when 
planning adjuvant or salvage radiotherapy. We recommend 
mpMR-guided RT rather than blind salvage RT.  
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Purpose/Objective: A subset of patients experience a PSA 
recurrence (rPSA) following radical prostatectomy. 
Radiotherapy can salvage those patients, provided that all 
disease is encompassed within the planning target volume 
(PTV) and a sufficient radiation dose is delivered. We 
hypothesized that these requirements can be achieved more 
adequately with MRI-guided radiation treatment planning. 
Materials and Methods: From January 2009 to April 2014, 238 
patients with rPSA were referred to our department for 
salvage radiotherapy. According to protocol, patients 
received a planning CT without IV contrast as well as a 
planning MRI in treatment position. MRI consisted of T1-, T2-, 
and diffusion-weighted (with an apparent diffusion 
coefficient (ADC) map) sequences. Dose to the prostate bed 
was 66.0 Gy in 33 fractions for all patients, delivered through 
intensity-modulated radiotherapy (IMRT). All MRI scans were 
reviewed by an experienced uro-radiologist. 
Results: Patients with a rPSA ≥ 5.0 µg/L or proven local 
recurrence were excluded from this analysis (n = 16). Of 222 
evaluable patients, 183 patients received both a planning CT 
and MRI while 39 patients only received a planning CT for 
various reasons. Patients were referred a mean 33.2 months 
(range: 6 – 161 months) after radical prostatectomy for a pT1 
(n = 1), pT2 (n = 108), pT3 (n = 68), or pT4 (n = 1) prostate 
adenocarcinoma (see Table). Median rPSA value at time of 
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referral was 0.32 µg/L (range: 0.016 – 4.65 µg/L). MRI did not 
show any suspected macroscopic disease in 137 patients 
(74.9%). In 46 (25.1%) patients, MRI did indicate a local (n = 
19) and/or pelvic (n = 29) recurrence, suspected bone lesions 
were observed in two patients. The mean rPSA was 
significantly higher in patients with a suspected recurrence 
on MRI than in patients with a negative MRI (0.42 µg/L vs. 
1.35 µg/L, p = 0.00002) on a Student t-test. The mean follow-
up was 33.1 months (range: 5 – 69 months). Biochemical 
disease-free survival was significantly worse in patients with 
suspected macroscopic disease on MRI (HR 2.867, p < 0.0001) 
(see Figure), this result remained independently significant 
after Multivariate Cox regression analysis (HR 2.496, 95% CI 
1.376 – 4.528, p = 0.0003). Furthermore, androgen 
deprivation therapy-free survival was significantly worse in 
patients with a suspected recurrence on MRI (HR 4.02, p < 
0.0001), this result also remained independently significant 
after Multivariate Cox regression analysis (HR 3.4, 95% CI 
1.524 - 7.591, p = 0.003). 
In a second analysis, the location of the suspected lesions will 
be correlated to the irradiated PTVs as well as the EORTC 
guidelines. Also, the volume of the recurrence will be 






Conclusions: MRI, especially with diffusion-weighted 
sequences, detects loco-regional disease in a substantial 
subset of patients with a biochemical recurrence after 
prostatectomy, particularly when rPSA is above 0.5 µg/L. 
Lack of MRI-based dose escalation on these macroscopic 
recurrences could explain some of the biochemical 
progression observed after salvage radiotherapy. 
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To aid in radiotherapy planning for the future, a series of 
recent studies on health economic aspects of radiation 
oncology in Europe have been published by HERO - the ESTRO 
Health Economics in Radiation Oncology project. HERO has 
the overall aim to develop a knowledge base of the provision 
of radiotherapy in Europe and build a model for health 
economic evaluation of radiation treatments at the European 
level. The first step has been to provide a validated picture 
of the European radiotherapy landscape in terms of 
availability of equipment, personnel and guidelines, and to 
estimate the need for radiotherapy in European countries. 
The access to radiotherapy was studied using an 84-item 
questionnaire, distributed to the 40 countries of the 
European Cancer Observatory. The results showed a huge 
variation in the availability and sophistication of treatment 
equipment and staffing levels across Europe. The median 
number of MV units per million inhabitants was 5.3, with a 
seven-fold variation across the European countries. Staffing 
figures showed a twenty-fold variation, even after grouping 
personnel with comparable duties in the radiotherapy 
process. Guidelines for equipment and human resources were 
declared for most countries, but without explicitly providing 
metrics for developing capital and human resource 
inventories in many cases. Both staffing and access to 
modern radiotherapy (IMRT and IGRT) was correlated to 
economic status (GNI/n), but large differences were observed 
also between countries with higher GNI/n, indicating that 
health policy has a significant impact on the provision of 
services. 
The evidence-based need for radiotherapy, in terms of 
number of cancer patients requiring radiotherapy, can be 
estimated from merging epidemiological data with evidence-
based clinical decision trees. The CCORE studies based on 
Australian data have indicated that about 50% of all cancer 
patients will at some point in their disease need 
radiotherapy. In a recent European HERO study these 
estimates have been refined with details about tumour site 
and stage relevant for each of the European countries. The 
results indicate that variations in tumour site more than 
stage influence this optimal proportion; on average 51% of 
European cancer patients are candidates for radiotherapy. 
A major question which is currently being explored by HERO 
is the discrepancy observed between the actual utilization 
and the optimal utilization of radiotherapy in European 
countries. A comparison to the actually delivered 
radiotherapy courses published in the HERO studies revealed 
that the optimal radiotherapy utilization benchmark is not 
met in the vast majority of countries, not even the most 
affluent and well-served countries. Reasons for this striking 
discrepancy may in some instances be directly related to lack 
of access to radiotherapy resources, but other factors 
including local and national treatment traditions, referral 
patterns, patient preferences, geography, co-morbidity, 
reimbursement rules etc. may also play significant roles. To 
uncover these mechanisms is important for radiation 
oncology and warrants further studies. 
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